Renshiyixue achieved full marks in 4 NCCL, CAP, and EMQN inter-laboratory assessments!

Recently, Ranshi Medical achieved a perfect score in four external quality assessment (EQA) programs organized by three authoritative organizations: the National Clinical Laboratory Center (NCCL) of the National Health Commission, the College of American Pathologists (CAP), and the European Molecular Genetics Diagnostic Quality Alliance (EMQN). To date, Ranshi Medical’s high-throughput sequencing (NGS) laboratory has successfully passed 323 external quality assessments from domestic and international authoritative organizations such as NCCL, PQCC, EMQN, and CAP!

The four EQA programs covered multiple solid tumors including hereditary breast and ovarian cancer, breast cancer, and others, involving various gene mutations and mutation types. The laboratory used Ranshi OncoScreen Plus, BRCA1/BRCA2 dual-gene white blood cell testing products, and successfully detected all mutations in 15 samples, fully validating Ranshi Medical’s detection accuracy and standardization across different testing technologies and sample types.

With over ten years of dedicated experience in the tumor NGS field, Ranshi Medical has always adhered to the philosophy of “Precision diagnosis and treatment, quality first,” and has established a comprehensive quality assurance system covering the entire testing process. Currently, the company has successfully passed the Guangdong Provincial Clinical Laboratory Center’s “High-Throughput Sequencing Laboratory” technical review and obtained multiple international quality certifications including CAP, CLIA, ISO15189, ISO9001, and GMP, providing multiple guarantees for standardized, accurate, and reliable testing results.

In the future, Ranshi Medical will continue to uphold high standards for laboratory operation, continuously iterate technology and optimize quality systems, and consistently provide better tumor precision diagnosis and treatment solutions for clinical research, innovative pharmaceutical companies, and patients, contributing to the high-quality development of global tumor precision medicine!

Assessment Details

NCCL External Quality Assessment

In the NCCL-organized “2025 Solid Tumor Somatic Mutation High-Throughput Sequencing Detection External Quality Evaluation,” the laboratory received 6 DNA samples and successfully detected clinically relevant targeted therapy-related genes using Ranshi OncoScreen Plus. The program covered mutation types such as point mutations, short fragment deletions and insertions (detection limit ≤5%), strictly meeting the quality assessment requirements. The laboratory achieved a perfect score, providing precise support for treatment decision-making in solid tumors.

CAP External Quality Assessment

In the CAP-organized “BRCA-B 2025 BRCA1/2 Sequencing (BRCA1/2)” proficiency test, the laboratory received 3 BRCA1/2 DNA samples from female patients with breast and ovarian cancer. Using the BRCA1/BRCA2 dual-gene white blood cell testing product, the lab accurately completed BRCA1/2 detection and result interpretation. Achieving a perfect score, this demonstrated Ranshi Medical’s compliance and reliability in hereditary tumor gene testing.

EMQN External Quality Assessment

In the EMQN-organized “ONCOGENE PANEL | 2025” and “BREAST CANCER (AKT pathway) [Tissue] | 2025” two external quality assessments, Ranshi Medical used Ranshi OncoScreen Plus series detection products to identify multiple core driver genes including EGFR, BRAF, KRAS, NRAS, KIT, PIK3CA, AKT1, PTEN, ERBB2, IDH2, etc., in 6 paraffin-embedded samples. The submitted English reports met international standards in gene typing, result interpretation, and documentation accuracy. Achieving a perfect score, this fully validated the comprehensiveness and accuracy of the products in multi-gene detection of solid tumors.